Integration of active human β-galactosidase gene (100kb) into genome using HSV/AAV amplicon vector

Gene Therapy

Volumn 14, Issue 14, 2007, Pages 1078-1091

  Oehmig, A ^a   Cortes M L ^a   Perry, K F ^a   Sena Esteves, M ^a   Fraefel, Cornel ^b   Breakefield, X O ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GALACTOSIDASE; PARVOVIRUS VECTOR;

ADENO ASSOCIATED VIRUS; AMPLICON; ANIMAL CELL; ARTICLE; CELL CLONE; CELL GROWTH; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME DEFICIENCY; GENE CASSETTE; GENE EXPRESSION; GENE FUNCTION; GENE LOCUS; GENE TARGETING; GENE VECTOR; GENOME; GLIOBLASTOMA; HERPES SIMPLEX VIRUS 1; HUMAN; HUMAN CELL; INVERTED TERMINAL REPEAT; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; TRANSGENE; TUMOR CELL; VIRUS HYBRID;

ANIMALS; BETA-GALACTOSIDASE; BLOTTING, SOUTHERN; CELL LINE, TRANSFORMED; CERCOPITHECUS AETHIOPS; DEPENDOVIRUS; FIBROBLASTS; GANGLIOSIDOSIS, GM1; GENE EXPRESSION; GENE THERAPY; GENETIC ENGINEERING; GENETIC VECTORS; GENOME; GREEN FLUORESCENT PROTEINS; HERPESVIRUS 1, HUMAN; HUMANS; TIME FACTORS; TRANSDUCTION, GENETIC; TRANSGENES; VIRUS INTEGRATION;

ADENO-ASSOCIATED VIRUS; HUMAN HERPESVIRUS 1;

EID: 34447103365     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/sj.gt.3302960     Document Type: Article

References (64)

1. Brentani H, Caballero OL, Camargo AA, da Silva AM, da Silva WAJ, Dias Neto E. The generation and utilization of a cancer-oriented representation of the human transcriptome by using expressed sequence tags. Proc Natl Acad Sci USA 2003; 100: 13418-13423.
2. Wade-Martins R, Saeki Y, Chiocca EA. Infectious delivery of a 135-kb LDLR genomic locus leads to regulated complementation of low-density lipoprotein receptor deficiency in human cells. Mol Therapy 2003; 7: 604-612.
3. McGeoch DJ, Dalrymple MA, Davison AJ, Dolan A, Frame MC, McNab D et al. The complete DNA sequence of the long unique region in the genome of herpes simplex virus type 1. J Gen Virol 1988; 69: 1531-1574.
4. Dolan A, Jamieson FE, Cunningham C, Barnett BC, McGeoch DJ. The genome sequence of herpes simplex virus type 2. J Virol 1998; 72: 2010-2021.
5. Spaete RR, Frenkel N. The herpes simplex virus amplicon: A new eucaryotic defective-virus cloning-amplifying vector. Cell 1982; 30: 295-304.
6. Cunningham C, Davison AJ. A cosmid-based system for constructing mutants of herpes simplex virus type 1. Virology 1993; 197: 116-124.
7. Saeki Y, Ichikawa T, Saeki A, Chiocca EA, Tobler K, Ackermann M et al. Herpes simplex virus type 1 DNA amplified as bacterial artificial chromosome in Escherichia coli: Rescue of replication-competent virus progeny and packaging of amplicon vectors. Hum Gene Therapy 1998; 9: 2787-2794.
8. Saeki Y, Fraefel C, Ichikawa T, Breakefield XO, Chiocca EA. Improved helper virus-free packaging system for HSV amplicon vectors using an ICP27-deleted, oversized HSV-1 DNA in a bacterial artificial chromosome. Mol Therapy 2001; 3: 591-601.
9. Wade-Martins R, Smith ER, Tyminski E, Chiocca EA, Saeki Y. An infectious transfer and expression system for genomic DNA loci in human and mouse cells. Nat Biotechnol 2001; 19: 1067-1070.
10. Inoue R, Moghaddam KA, Ranasinghe M, Saeki Y, Chiocca EA, Wade-Martins R. Infectious delivery of the 132 kb CDKN2A/CDKN2B genomic DNA region results in correctly spliced gene expression and growth suppression in glioma cells. Gene Therapy 2004; 11: 1195-1204.
11. Xing W, Baylink D, Kesavan C, Mohan S. HSV-1 amplicon-mediated transfer of 128-kb BMP-2 genomic locus stimulates osteoblast differentiation in vitro. Biochem Biophys Res Commun 2004; 319: 781-786.
12. Logvinoff C, Epstein AL. Intracellular Cre-mediated deletion of the unique packaging signal carried by a herpes simplex virus type 1 recombinant and its relationship to the cleavage-packaging process. J Virol 2000; 74: 8402-8412.
13. Logvinoff C, Epstein AL. Genetic engineering of herpes simplex virus and vector genomes carrying loxP sites in cells expressing Cre recombinase. Virology 2000; 267: 102-110.
14. Logvinoff C, Epstein AL. A novel approach for herpes simplex virus type 1 amplicon vector production, using the Cre-loxP recombination system to remove helper virus. Hum Gene Therapy 2001; 12: 161-167.
15. Wang S, Vos JM. A hybrid herpesvirus infectious vector based on Epstein-Barr virus and herpes simplex virus type 1 for gene transfer into human cells in vitro and in vivo. Lineberger Compreh 1996; 70: 8422-8430.
16. Liu Q, Perez CF, Wang Y. Efficient site-specific integration of large transgenes by an enhanced herpes simplex virus/adeno-associated virus hybrid amplicon vector. J Virol 2006; 80: 1672-1679.
17. Bakowska JC, Di Maria MV, Camp SM, Wang Y, Allen PD, Breakefield XO. Targeted transgene integration into transgenic mouse fibroblasts carrying the full-length human AAVS1 locus mediated by HSV/AAV rep(+) hybrid amplicon vector. Gene Therapy 2003; 10: 1691-1702.
18. Heister T, Heid I, Ackermann M, Fraefel C. Herpes simplex virus type 1/ adeno-associated virus hybrid vectors mediate site-specific integration at the adeno-associated virus preintegration site, AAVS1, on human chromosome 19. J Virol 2002; 76: 7163-7173.
19. Kotin RM, Menninger JC, Ward DC, Berns KI. Mapping and direct visualization of a region-specific viral DNA integration site on chromosome 19q13-qter. Genomics 1991; 10: 831-834.
20. Kotin RM, Linden RM, Berns KI. Characterization of a preferred site on human chromosome 19q for integration of adeno-associated virus DNA by non-homologous recombination. EMBO J 1992; 11: 5071-5078.
21. Samulski RJ, Zhu X, Xiao X, Brook JD, Housman DE, Epstein N et al. Targeted integration of adeno-associated virus (AAV) into human chromosome 19. EMBO J 1991; 10: 3941-3950.
22. Hong G, Ward P, Berns KI. In vitro replication of adeno-associated virus DNA. Proc Natl Acad Sci USA 1992; 89: 4673-4677.
23. Weitzman MD, Kyostio SR, Kotin RM, Owens RA. Adeno-associated virus (AAV) Rep proteins mediate complex formation between AAV DNA and its integration site in human DNA. Proc Natl Acad Sci USA 1994; 91 5808-5812.
24. Surosky RT, Urabe M, Godwin SG, McQuiston SA, Kurtzman GJ, Ozawa K et al. Adeno-associated virus Rep proteins target DNA sequences to a unique locus in the human genome. J Virol 1997; 71: 7951-7959.
25. Linden RM, Winocour E, Berns KI. The recombination signals for adeno-associated virus site-specific integration. Proc Natl Acad Sci USA 1996; 93: 7966-7972.
26. Philpott NJ, Gomos J, Berns KI, Falck-Pedersen E. A p5 integration efficiency element mediates Rep-dependent integration into AAVS1 at chromosome 19. Proc Natl Acad Sci USA 2002; 99: 12381-12385.
27. Lam PY, Breakefield XO. Hybrid vector designs to control the delivery, fate and expression of transgenes. J Gene Med 2000; 2: 395-408.
28. Oehmig A, Fraefel C, Breakefield XO, Ackermann M. Herpes simplex virus type 1 amplicons and their hybrid virus partners, EBV, AAV, and retrovirus. Curr Gene Therapy 2004; 4: 385-408.
29. Wang Y, Camp SM, Niwano M, Shen X, Bakowska JC, Breakefield XO et al. Herpes simplex virus type 1/adeno-associated virus rep(+) hybrid amplicon vector improves the stability of transgene expression in human cells by site-specific integration. J Virol 2002; 76: 7150-7162.
30. Suzuki Y, Oshima A. A beta-galactosidase gene mutation identified in both Morquio B disease and infantile GM1 gangliosidosis. Hum Genet 1993; 91: 407.
31. Shows TB, Scrafford-Wolff LR, Brown JA, Meisler MH. GM1-gangliosidosis: chromosome 3 assignment of the beta-galactosidase-A gene (beta GALA). Somatic Cell Genet 1979; 5: 147-158.
32. Morreau H, Bonten E, Zhou XY, D'Azzo A. Organization of the gene encoding human lysosomal beta-galactosidase. DNA Cell Biol 1991; 10: 495-504.
33. Hinek A, Zhang S, Smith AC, Callahan JW. Impaired elastic-fiber assembly by fibroblasts from patients with either Morquio B disease or infantile GM1-gangliosidosis is linked to deficiency in the 67-kD spliced variant of beta-galactosidase. Am J Hum Genet 2000; 67: 23-36.
34. Caciotti A, Donati MA, Bardelli T, d'Azzo A, Massai G, Luciani L et al. Primary and secondary elastin-binding protein defect leads to impaired elastogenesis in fibroblasts from GM1-gangliosidosis patients. Am J Pathol 2005; 167: 1689-1698.
35. Cheng SH, Smith AE. Gene therapy progress and prospects: Gene therapy of lysosomal storage disorders. Gene Therapy 2003; 10: 1275-1281.
36. Kornfeld S. Trafficking of lysosomal enzymes. FASEB J 1987; 1 462-468.
37. Hahn CN, del Pilar Martin M, Schroder M, Vanier MT, Hara Y, Suzuki K et al. Generalized CNS disease and massive GM1-ganglioside accumulation in mice defective in lysosomal acid beta-galactosidase. Hum Mol Genet 1997; 6: 205-211.
38. Matsuda J, Suzuki O, Oshima A, Ogura A, Noguchi Y, Yamamoto Y et al. Beta-galactosidase-deficient mouse as an animal model for GM1-gangliosidosis. Glycoconj J 1998; 14: 729-736.
39. Bantel-Schaal U, zur Hausen H. Adeno-associated viruses inhibit SV40 DNA amplification and replication of herpes simplex virus in SV40-transformed hamster cells. Virology 1988; 164: 64-74.
40. Laughlin CA, Cardellichio CB, Coon HC. Latent infection of KB cells with adeno-associated virus type 2. J Virol 1986; 60: 515-524.
41. McLaughlin SK, Collis P, Hermonat PL, Muzyczka N. Adeno-associated virus general transduction vectors: Analysis of proviral structures. J Virol 1988; 62: 1963-1973.
42. Kotin RM, Siniscalco M, Samulski RJ, Zhu XD, Hunter L, Laughlin CA et al. Site-specific integration by adeno-associated virus. Proc Natl Acad Sci USA 1990; 87: 2211-2215.
43. Philpott NJ, Giraud-Wali C, Dupuis C, Gomos J, Hamilton H, Berns KI et al. Efficient integration of recombinant adeno-associated virus DNA vectors requires a p5-rep sequence in cis. J Virol 2002; 76 5411-5421.
44. Goncalves MA, van Nierop GP, Tijssen MR, Lefesvre P, Knaan-Shanzer S, van der Velde I et al. Transfer of the full-length dystrophin-coding sequence into muscle cells by a dual high-capacity hybrid viral vector with site-specific integration ability. J Virol 2005; 79: 146-162.
45. Zarrin AA, Malkin L, Fong I, Luk KD, Ghose A, Berinstein NL. Comparison of CMV, RSV, SV40 viral and Vlambda1 cellular promoters in B and T lymphoid and non-lymphoid cell lines. Biochim Biophys Acta 1999; 1446: 135-139.
46. Heilbronn R, Burkle A, Stephan S, zur Hausen H. The adeno-associated virus rep gene suppresses herpes simplex virus-induced DNA amplification. J Virol 1990; 64: 3012-3018.
47. Weitzman MD, Fisher KJ, Wilson JM. Recruitment of wild-type and recombinant adeno-associated virus into adenovirus replication centers. J Virol 1996; 70: 1845-1854.
48. Recchia A, Parks RJ, Lamartina S, Toniatti C, Pieroni L, Palombo F et al. Site-specific integration mediated by a hybrid adeno-virus/ adeno-associated virus vector. Proc Natl Acad Sci USA 1999; 96 2615-2620.
49. Recchia A, Perani L, Sartori D, Olgiati C, Mavilio F. Site-specific integration of functional transgenes into the human genome by adeno/AAV hybrid vectors. Mol Therapy 2004; 10: 660-670.
50. Balague C, Kalla M, Zhang WW. Adeno-associated virus Rep78 protein and terminal repeats enhance integration of DNA sequences into the cellular genome. J Virol 1997; 71: 3299-3306.
51. Xiao K, Li J, Samulski RJ. Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector. J Virol 1996; 70: 8098-8108.
52. Xiao X, XiaoW, Li J, Samulski RJ. A novel 165-base-pair terminal repeat sequence is the sole cis requirement for the adeno-associated virus life cycle. J Virol 1997; 71: 941-948.
53. Lamartina S, Ciliberto G, Toniatti C. Selective cleavage of AAVS1 substrates by the adeno-associated virus type 2 rep68 protein is dependent on topological and sequence constraints. J Virol 2000; 74: 8831-8842.
54. Miller DG, Trobridge GD, Petek LM, Jacobs MA, Kaul R, Russell DW. Large-scale analysis of adeno-associated virus vector integration sites in normal human cells. J Virol 2005; 79: 11434-11442.
55. Wang H, Lieber A. A helper-dependent caspid-modified adenovirus vector expressing AAV-Rep 78 mediates site-specific integration of a 27kb transgene cassette. J Virol 2006; 80: 11699-11709.
56. Mendelson E, Smith MG, Miller IL, Carter BJ. Effect of a viral rep gene on transformation of cells by an adeno-associated virus vector. Virology 1988; 166: 612-615.
57. Samulski RJ, Chang LS, Shenk T, Fisher KJ, Jooss K, Alston J et al. Helper-free stocks of recombinant adeno-associated viruses: Normal integration does not require viral gene expression. J Virol 1989; 63: 3822-3828.
58. Datsenko KA, Wanner BL. One-step inactivation of chromosomal genes in Escherichia coli K-12 using PCR products. Proc Natl Acad Sci USA 2000; 97: 6640-6645.
59. Saeki Y, Breakefield XO, Chiocca EA. Improved HSV-1 amplicon packaging system using ICP27-deleted, oversized HSV-1 BAC DNA. In: Machida CA (ed). Viral Vectors for Gene Therapy, Methods and Protocols. Human Press: Totowa, New Jersey, 2003, pp 51-60.
60. Oshima A, Tsuji A, Nagao Y, Sakuraba H, Suzuki Y. Cloning, sequencing, and expression of cDNA for human beta-galactosidase. Biochem Biophys Res Commun 1988; 157: 238-244.
61. Smith IL, Hardwicke MA, Sandri-Goldin RM. Evidence that the herpes simplex virus immediate early protein ICP27 acts post-transcriptionally during infection to regulate gene expression. Virology 1992; 186: 74-86.
62. Breakefield XO, Braverman M, Riker DK, Giller ELJ. Catechol-O-methyltransferase activity in cultured human skin fibroblasts from controls and patients with dystonia musculorum deformans. J Neurosci Res 1981; 6: 349-360.
63. Sena-Esteves M, Hampl JA, Camp SM, Breakefield XO. Generation of stable retrovirus packaging cell lines after transduction with herpes simplex virus hybrid amplicon vectors. J Gene Med 2002; 4: 229-239.
64. Suzuki K. Enzymatic diagnosis of sphingolipidoses. Meth Enzymol 1987; 138: 727-762.